US FDA mulls int'l genomically-driven drugs trial to tackle breast cancer
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is to look into developing an international genomically-driven trial as part of efforts to accelerate the development of targeted drugs for patients with metastatic breast cancer1.